Se citan los principales ensayos clínicos en prevención cardiovascular concluidos en el último año. Se revisan el concepto y la fisiopatología del síndrome metabólico, su prevalencia en nuestro medio, los medios diagnósticos más adecuados y la necesidad de establecer medidas preventivas.
Palabras clave
Síndrome metabólico
Resistencia a la insulina
Dislipemia
Obesidad
Hipertensión arterial
Prevención cardiovascular
Este artículo solo puede leerse en
pdf
Bibliografía
[1.]
C.P. Cannon, E. Braunwald, C.H. McCabe, D.J. Rader, J.L. Rouleau, R. Belder, et al.
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
N Engl J Med, (2004), 350 pp. 1495-1504
[2.]
S.E. Nissen, E.M. Tyzan, P. Schoenhagen, B.G. Brown, P. Ganz, R.A. Vogel.
Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis.
JAMA, (2004), 291 pp. 1071-1089
[3.]
H.M. Colhoun, D.J. Betteridge, P.N. Durrington, G.A. Hitman, H.A. Neil, S.J. Livingstone, et al.
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
Lancet, (2004), 364 pp. 685-696
[4.]
M.E. Brousseau, E.J. Schaefer, M.L. Wolfe, L.T. Bloedon, A.G. Digenio, R.W. Clark, et al.
Effects of an inhibitor of cholesterol ester transfer protein on HDL cholesterol.
N Engl J Med, (2004), 350 pp. 1505-1515
[5.]
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-421.
[6.]
S.M. Grundy, J.I. Cleeman, C.N. Merz, H.B. Brewer Jr, L.T. Clark, D.B. Hunninghake, et al.
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
Circulation, (2004), 110 pp. 227-239
[7.]
E. Kylin.
Studien uber das hypertonie-hyperglykämie-hyperurikämiesyndrom.
Zentralblatt Fuer Innnere Med, (1923), 44 pp. 105-127
[8.]
T.A. Welborn, A. Breckenridge, A.H. Rubinstein, C.T. Dollery, T.R. Fraser.
Serum-insulin in essential hypertension and in peripheral vascular disease.
Lancet, (1966), 1 pp. 1336-1337
[9.]
M. Modan, H. Halkin, S. Almog, A. Lusky, A. Eshkol, M. Shefi, et al.
Hyperinsulinemia. A link between hypertension obesity and glucose intolerance.
J Clin Invest, (1985), 75 pp. 809-817
[10.]
G.M. Reaven.
Banting lecture 1988. Role of insulin resistance in human disease.
Diabetes, (1988), 37 pp. 1595-1607
[11.]
I. Hjermann.
The metabolic cardiovascular syndrome: syndrome X, Reaven's syndrome, insulin resistance syndrome, atherothrombogenic syndrome.
J Cardiovasc Pharmacol, (1992), 20 pp. 5-10
[12.]
H. Beck-Nielsen.
General characteristics of the insulin resistance syndrome: prevalence and heritability. European Group for the study of Insulin Resistance (EGIR).
Drugs, (1999), 58 pp. 7-10
[13.]
H. Arnesen.
The metabolic cardiovascular syndrome.
J Cardiovas Pharmacol, (1992), 20 pp. 1S
[14.]
B. Balkau, M.A. Charles.
Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR).
Diabet Med, (1999), 16 pp. 442-443
[15.]
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
[16.]
G.M. Reaven.
Pathophysiology of insulin resistance in human disease.
Physiol Rev, (1995), 75 pp. 473-486
[17.]
S.M. Grundy.
Hypertriglyceridemia, insulin resistance, and the metabolic syndrome.
Am J Cardiol, (1999), 83 pp. 25F-29F
[18.]
J.B. Meigs.
Invited commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors.
Am J Epidemiol, (2000), 152 pp. 908-911
[19.]
D.E. Moller, J.S. Flier.
Insulin resistante: Mechanisms, syndromes and implications.
N Engl J Med, (1991), 325 pp. 938-945
[20.]
I.S. Okosun, Y. Liao, C.N. Rotimi, T.E. Prewitt, R.S. Cooper.
Abdominal adiposity and clustering of multiple metabolic syndrome in White, Black and Hispanic americans.
Ann Epidemiol, (2000), 10 pp. 263-270
[21.]
P. Zimmet, E.J. Boyko, G.R. Collier, M. De Courten.
Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players.
Ann N Y Acad Sci, (1999), 892 pp. 25-44
[22.]
C. Weyer, T. Funahashi, S. Tanaka.
Hyperadiponectinemia in obesisty and type 2 Diabetes; close association with insulin resistance and hyperinsulinemia.
J Clin Endocrinol Metab, (2001), 86 pp. 1930-1935
[23.]
J.S. Yudkin, C.D. Stehouwer, J.J. Emeis, S.W. Coppack.
C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?.
Arterioscler Thromb Vasc Biol, (1999), 19 pp. 972-978
[24.]
S.I. Itani, N.B. Ruderman, F. Schmieder, G. Boden.
Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha.
Diabetes, (2002), 51 pp. 2005-2011
[25.]
G. Boden, P. Cheung, T.P. Stein, K. Kresge, M. Mozzoli.
FFA cause hepatic insulin resistance by inhibiting insulin suppression of glycogenolysis.
Am J Physiol Endocrinol Metab, (2002), 283 pp. 12-19
[26.]
H.O. Steinberg, M. Tarshoby, R. Monestel, G. Hook, J. Cronin, A. Johnson, et al.
Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation.
J Clin Invest, (1997), 100 pp. 1230-1239
[27.]
S. Klein, L. Fontana, V.L. Young, A.R. Coggan, C. Kilo, B.W. Patterson, et al.
Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease.
N Engl J Med, (2004), 350 pp. 2549-2557
[28.]
L.C. Groop.
Insulin resistance: the fundamental trigger of type 2 diabetes.
Diabetes Obes Metab, (1999), 1 pp. 1-7
[29.]
M.K. Cavaghan, D.A. Ehrmann, K.S. Polonsky.
Interactions between insulin resistance and insulin secretion in the development of glucose intolerance.
J Clin Invest, (2000), 106 pp. 329-333
[30.]
D. Tripathy, M. Carlsson, P. Almgren, B. Isomaa, M.R. Taskinen, T. Tuomi, et al.
Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study.
Diabetes, (2000), 49 pp. 975-980
[31.]
Grupo de Trabajo de Resistencia a la Insulina de la Sociedad Española de Diabetes.
Resistencia a la insulina y su implicación en múltiples factores de riesgo asociados a la diabetes tipo 2.
Med Clin (Barc), (2002), 119 pp. 458-463
[32.]
D.W. Erkelens.
Diabetic dyslipidaemia.
Eur Heart J, (1998), 19 pp. 27-40
[33.]
E. Ferrannini, G. Buzzigoli, R. Bonadonna, M.A. Giorico, M. Oleggini, L. Graziadei, et al.
Insulin resistance in essential hypertension.
N Engl J Med, (1987), 317 pp. 350-357
[34.]
L. Lind, C. Berne, H. Lithell.
Prevalence of insulin resistance in essential hypertension.
J Hypertens, (1995), 13 pp. 1457-1462
[35.]
E. Ferrannini, S.M. Haffner, B.D. Mitchell, M.P. Stern.
Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome.
Diabetologia, (1991), 34 pp. 416-422
[36.]
P. Ferrari, P. Weidmann, S. Shaw, D. Giachino.
Altered insulin sesitivity, hyperinsulinemia and dyslipemia in individuals with a hypertensive parent.
Am J Med, (1991), 91 pp. 589-596
[37.]
E.A. Anderson, R.P. Hoffman, T.W. Balon, C.A. Sinkey, A.L. Mark.
Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans.
J Clin Invest, (1991), 87 pp. 2246-2252
[38.]
J. Cabezas-Cerrato.
Síndrome metabólico e hipertensión arterial: una relación difícil.
Cardiovascular Risk Factors, (2003), 12 pp. 96-104
[39.]
U. Scherrer, D. Randin, P. Vollenweider, L. Vollenweider, P. Nicod.
Nitric oxide release accounts for insulin's vascular effects in humans.
J Clin Invest, (1994), 94 pp. 2511-2515
[40.]
H.O. Steinberg, G. Brechtel, A. Johnson, N. Fineberg, A.D. Baron.
Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release.
J Clin Invest, (1994), 94 pp. 1172-1179
[41.]
J.R. Petrie, S. Ueda, D.J. Webb, H.L. Elliott, J.M. Connell.
Endothelial nitric oxide production and insulin sensitivity. A physiological link with implications for pathogenesis of cardiovascular disease.
Circulation, (1996), 93 pp. 1331-1333
[42.]
A.W. Miller, C. Tulbert, M. Puskar, D.W. Busija.
Enhanced endothelin activity prevents vasodilation to insulin in insulin resistance.
Hypertension, (2002), 40 pp. 78-82
[43.]
R.A. Bastarrachea, A. Shelley, A. Cole, G. Comuzzie.
Genómica de la regulación del peso corporal: mecanismos moleculares que predisponen a la obesidad.
Med Clin (Barc), (2004), 123 pp. 104-117
[44.]
Y.C. Chagnon, T. Rankinen, E.E. Snyder, S.J. Weisnagel, L. Perusse, C. Bouchard.
The human obesity gene map: The 2002 update.
Obes Res, (2003), 11 pp. 313-367
[45.]
Y. Kagawa, Y. Yanagisawa, K. Hasegawa, H. Suzuki, K. Yasuda, H. Kudo, et al.
Single nucleotide polymorphisms of thrifty genes for energy metabolism: evolutionary origins and prospects for intervention to prevent obesity-related diseases.
Biochem Biophys Res Commun, (2002), 295 pp. 207-222
[46.]
L.S. Cheng, R.C. Davis, L.J. Raffel, A.H. Xiang, N. Wang, M. Quinones, et al.
Coincident linkage of fasting plama insulin and blood pressure to cromosoma 7q in hypertensive hispanic families.
Circulation, (2001), 104 pp. 1255-1260
[47.]
E.S. Ford, W.H. Giles, W.H. Dietz.
Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey.
JAMA, (2002), 287 pp. 356-359
[48.]
M.P. Reilly, D.J. Rader.
The metabolic syndrome: more than the sum of it's parts?.
Circulation, (2003), 108 pp. 1546-1551
[49.]
J.B. Meigs, P.W. Wilson, D.M. Nathan, R.B. D’Agostino, K. Williams, S.M. Haffner.
Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies.
Diabetes, (2003), 52 pp. 2160-2167
[50.]
P.M. Ridker, J.E. Buring, N.R. Cook, N. Rifai.
C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women.
Circulation, (2003), 107 pp. 391-397
[51.]
A. Grima, E. Alegría, P. Jover.
Prevalencia de los factores de riesgo clásicos en una población laboral mediterránea de 4.996 varones.
Rev Esp Cardiol, (1999), 52 pp. 910-918
[52.]
F. Rodríguez Artalejo, E. López García, J.L. Gutiérrez-Fisac, J.R. Banegas Banegas, P.J. Lafuente Urdinguio, V. Domínguez Rojas.
Changes in the prevalence of overweight and obesity and their risk factors in Spain, 1987-1997.
Prev Med, (2002), 34 pp. 72-81
[53.]
J.R. González Juanatey, E. Alegría Ezquerra, J.V. Lozano Vidal, J.L. Llisterri Caro, J.M. Isidoro González Maqueda.
Impacto de la hipertensión en las cardiopatías en España. Estudio Cardiotens 1999.
Rev Esp Cardiol, (2001), 54 pp. 139-149
[54.]
E.E. Álvarez, L. Ribas, L. Serra.
Prevalencia del síndrome metabólico en la Comunidad Canaria.
Med Clin (Barc), (2003), 120 pp. 172-174
[55.]
A. Hernández Mijares, C. Riera Fortuny, E. Sola Izquierdo, M.J. Oliver Oliver, M.L. Martínez Triguero, C. Morillas Arino, et al.
Prevalencia del síndrome metabólico entre pacientes con cardiopatía isquémica.
Med Clin (Barc), (2003), 121 pp. 204-208
[56.]
J.F. Ascaso, P. Romero, J.T. Real, R.I. Lorente, J. Martínez-Valls, R. Carmena.
Abdominal obesity, insulin resistance, and metabolic syndrome in a southern European population.
Eur J Intern Med, (2003), 14 pp. 101-106
[57.]
C. Lorenzo, M. Serrano-Ríos, M.T. Martínez-Larrad, R. Gabriel, K. Williams, J.A. Gómez-Gerique, et al.
Central adiposity determines prevalence differences of the Metabolic syndrome.
Obes Res, (2003), 11 pp. 1480-1487
[58.]
N. Sattar, A. Gaw, O. Scherbakova, I. Ford, D.S. O’Reilly, S.M. Haffner, et al.
Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study.
Circulation, (2003), 108 pp. 414-419
[59.]
K.G. Alberti, P.Z. Zimmet, For the WHO Consultation.
Definition, diagnosis and classification of diabetes mellitus, personal report of a WHO consultation.
Diabetes Med, (1998), 15 pp. 539-553
[60.]
S.M. Grundy, H.B. Brewer, J.L. Allman, S.C. Smith, C. Lenfant, For the Conference participants.
Definition of Metabolic Syndrome. Report of the Nacional Heart, Lung and Blood Institute. American Heart Association Conference on Scientific issues related to definition.
Circulation, (2004), 109 pp. 433-438
[61.]
K.L. Cheal, F. Abassi, C. Lamendala, T. McLaughlin, G.M. Reaven, E.S. Ford.
Relationship to insulin resistence of the Adult Treatment Panel III diagnostic criteria for identification of the Metabolic Syndrome.
Diabetes Care, (2004), 53 pp. 1196-1200
[62.]
E.S. Ford.
The Metabolic Syndrome and C-Reactive Protein, fibrinogen and leukocyte count findings from the Third National Health and Nutrition Examination Survey.
Atherosclerosis, (2003), 168 pp. 351-358
[63.]
S. Tonstad, I. Hjermann.
A high risk score for coronary heart disease is associated with the metabolic syndrome in 40-year-old-men and women.
Journal of Cardiovascular Risk, (2003), 10 pp. 129-135
[64.]
G. Assmann, P. Cullen, F. Jossa, B. Lewis, M. Mancini.
Coronary heart disease: reducing the risk: the scientific background to primary and secondary prevention of coronary heart disease. A worldwide view. International Task force for the Prevention of Coronary Heart disease.
Arterioscler Thromb Vasc Biol, (1999), 19 pp. 1819-1824
[65.]
P. Lempiainen, L. Mykkanen, K. Pyorala, M. Laakso, J. Kuusisto.
Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men.
Circulation, (1999), 100 pp. 123-128
[66.]
P.A. Sakkinen, P. Wahl, M. Cushman, M.R. Lewis, R.P. Tracy.
Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome.
Am J Epidemiol, (2000), 152 pp. 897-907
[67.]
J.A. Gimeno Orna, L.M. Lou Arnal, E. Molinero Herguedas, B. Boned Julián, D.P. Portilla Córdoba.
Influencia del síndrome metabólico en el riesgo cardiovascular de pacientes con diabetes tipo 2.
Rev Esp Cardiol, (2004), 57 pp. 507-513
[68.]
H.M. Lakka, D.E. Laaksonen, T.A. Lakka, L.K. Niskanen, E. Kumpusalo, J. Tuomilehto, et al.
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men.
JAMA, (2002), 288 pp. 2709-2716
[69.]
G. Hu, Q. Qiao, J. Tuomilehto, B. Balkau, K. Borch-Johnsen, K. Pyorala.
Prevalence of the metabolic syndrome and its relation to allcause and cardiovascular mortality in nondiabetic European men and women.
Arch Intern Med, (2004), 164 pp. 1066-1076
[70.]
I. Plaza Pérez, F. Villar Álvarez, P. Mata López, F. Pérez Jiménez, A. Maiquez Galán, J.A. Casasnovas Lenguas, et al.
Control de la colesterolemia en España, 2000. Un instrumento para la prevención cardiovascular.
Rev Esp Cardiol, (2000), 53 pp. 815-837
[71.]
J.A. Velasco, J. Cosín, J.M. Maroto, J. Muñiz, J.A. Casasnovas, I. Plaza, et al.
Guías de práctica clínica de la Sociedad Española de Cardiología en prevención cardiovascular y rehabilitación cardíaca.
Rev Esp Cardiol, (2000), 53 pp. 1095-1120
[72.]
A. Garg, J.P. Bantle, R.R. Henry, A.M. Coulston, K.A. Griver, S.K. Raatz, et al.
Effects of varying carbohydrate content of diet in patients with non- insulin-dependent diabetes mellitus.
JAMA, (1994), 271 pp. 1421-1428
[73.]
D.R. Dengel, A.T. Galecki, J.M. Hagberg, R.E. Pratley.
The independent and combined effects of weight loss and aerobic exercise on blood pressure and oral glucose tolerance in older men.
Am J Hypertens, (1998), 11 pp. 1405-1412
[74.]
G. Perseghin, T.B. Price, K.F. Petersen, M. Roden, G.W. Cline, K. Gerow, et al.
Increased glucose transport-phosphorylation and muscle glycogen synthesis after exercise training in insulin-resistant subjects.
N Engl J Med, (1996), 335 pp. 1357-1362
[75.]
G. Reaven, K. Seagal, J. Hauptman, M. Boldrin, C. Lucas.
Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X.
Am J Cardiol, (2001), 87 pp. 827-831
[76.]
A.V. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, J.L. Izzo Jr., et al.
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
Hypertension, (2003), 42 pp. 1206-1252
Copyright ©
2005. Sociedad Española de Cardiología